In a multinational cohort of 2473 patients enrolled from 2006-2017, factors associated with worse overall survival from the time of diagnosis of breast cancer brain metastases (“BCBrM”) included KPS (18, 19) (≤60 vs 70-80 vs 90-100), age (≥60 vs <60), extracranial metastases (presence vs absence), number of BrM (≥2 vs 1), and molecular subtype (HER2 vs luminal B vs luminal A vs basal) (8). This evidence concerns the gene ERBB2 and breast cancer.